TL;DR — NMN restores the NAD+ pool that fuels SIRT3 mitophagyA specific form of autophagy that selectively removes damaged or dysfunctional mitochondria, replacing them with healthy ones. Full glossary →, PARP DNA repair, and metabolic sensing. Tier A human data for raising NAD+A molecule every cell needs for energy production, DNA repair, and activating longevity genes (sirtuins). Full glossary → metabolites; start 250 mg AM fasted for 12+ weeks; pair PM resveratrol for SIRT1; retest NAD+ at week 4.
What NMN does (and why it matters)
Cellular NAD+ declines roughly 50% between ages 40–60. That coenzyme is not optional — it powers sirtuinsLongevity-associated enzymes that repair DNA, regulate metabolism, and control inflammation. Full glossary →, PARP-mediated strand repair, and CD38-regulated immune signaling. When NAD+ drops, mitochondria lose quality control first; epigenetic drift and senescence follow.
NMN is a direct NAD+ precursor that bypasses the age-impaired NAMPT salvage step in many tissues.
Primary hallmarks targeted: Mitochondrial dysfunction · Genomic instability · Epigenetic alterations · Cellular senescence · Deregulated nutrient sensing
Yi et al. GeroScience 2022 (PMID 36482258): in 80 healthy middle-aged adults over 60 days, NMN at 300, 600 or 900 mg/day raised blood NAD+ dose-dependently — the largest effect was at 600 mg, not at the highest dose tested. Yoshino et al. Science 2021 (PMID 33888596): 250 mg/day for 10 weeks improved skeletal muscle insulin sensitivity in postmenopausal prediabetic women. Liao et al. J Int Soc Sports Nutr 2021 (PMID 34238308): 300–1200 mg/day for 6 weeks improved aerobic capacity in 48 amateur runners.
Mechanism — fuel before activation
| Enzyme | NAD+ role | Hallmark link |
|---|---|---|
| SIRT3 | Deacetylates mitochondrial enzymes; enables mitophagy | Mitochondrial dysfunction |
| SIRT1 | Histone + metabolic sensor | Epigenetic alterations |
| PARP1 | Consumes NAD+ repairing DNA breaks | Genomic instability |
| CD38 | NAD+ degrading enzyme (rises with age/inflammation) | Chronic inflammation |
NMN vs NR: Both raise NAD+ in humans. TNiC standardizes on NMN for stack integration and published trial dosing. Either is defensible; do not combine high doses of both without physician oversight.
When NMN is worth your money
NMN earns a stack slot when two or more apply:
- NAD+ index below 80 (or never tested with age 45+ and declining energy)
- Mitochondrial hallmark is your primary target
- You already run Zone 2 + sleep basics for 4+ weeks
- You plan PM resveratrol or run the NAD+ Mito Stack
Skip or defer if sleep is under 6 hours, alcohol is heavy, or you have not fixed lifestyle foundation — NAD+ cannot substitute for biogenesis signals from exercise.
Evidence summary
| Study | Design | Dose | Duration | Key outcomes | Tier |
|---|---|---|---|---|---|
| Yi 2022 (36482258) | RCT, dose-ranging (n=80) | 300 / 600 / 900 mg | 60 d | ↑ NAD+ dose-dependently; peak effect at 600 mg | A |
| Liao 2021 (34238308) | RCT, amateur runners (n=48) | 300 / 600 / 1200 mg | 6 wk | ↑ Aerobic capacity | A |
| Yoshino 2021 (33888596) | RCT, postmenopausal prediabetic women | 250 mg | 10 wk | ↑ Muscle insulin sensitivity | A |
| Rajman 2018 (29514064) | Review | — | — | Therapeutic potential of NAD+-boosting molecules: the in vivo evidence | — |
← Swipe for more columns →
On dose: the only dose-ranging trial above (Yi 2022) found the largest NAD+ effect at 600 mg/day — not at its highest tested dose of 900 mg. The 250 mg figure used throughout this page comes from Yoshino 2021, the one cited trial that tested it.
Consensus: Tier A for NAD+ restoration in humans. Tier B for healthspanThe portion of life spent in good health, free from chronic disease or disability — distinct from lifespan (total years alive). Full glossary →/mortality claims — no completed longevity endpoint trials in people. Mouse data is consistently positive.
Where NMN disappoints
- Young, healthy adults with normal NAD+. The 50% decline is an aging phenomenon — restoring a pool that isn't depleted yields little measurable benefit. NMN is a correction, not an enhancement. - Energy that's actually a sleep or training deficit. NMN cannot manufacture the mitochondrial biogenesis signal that Zone 2 and adequate sleep provide. People chasing "more energy" while under-slept are usually disappointed. - The gap between biomarker and outcome. NAD+ metabolites rise reliably; the functional payoff (aerobic capacity, insulin sensitivity) rests on a handful of modest trials, and how much intact oral NMN enters cells — versus being dephosphorylated to NR first — is still debated.
Should you start NMN?
Sleep 7+ hrs and Zone 2 ≥150 min/wk for 4+ weeks?
node | NAD+ below 80 OR morning energy ≤5/10?
Start NMN 250 mg AM fasted → retest NAD+ week 4
Maintain lifestyle 8 more weeks → reassess subjective energy
Fix sleep + exercise first — NAD+ precursors are second-line
Active cancer treatment, pregnancy, or unexplained muscle pain → physician clearance before NAD+ precursors
Educational decision aid — a way to organize the evidence, not a prescription. Doses and timing shown are those used in studies; confirm anything you act on with a clinician or pharmacist.
What would change this grade. The tier is A for raising NAD+, not for extending healthspan. It would earn an outcome-level grade only with a completed, adequately powered human trial showing a hard functional or longevity endpoint — none is finished yet. It would fall to B if larger trials confirm NAD+ rises without any downstream functional benefit, which remains a live possibility.
Dosing protocol
| Parameter | Recommendation | Notes |
|---|---|---|
| Dose | 250–500 mg/day | Start 250 mg — the dose Yoshino 2021 (33888596) tested; titrate at week 12 if flat |
| Timing | AM, fasted or light stomach | Avoid high-dose niacin (flush form) |
| Form | Stabilized capsule | Refrigerate if label recommends |
| PM pair | Trans-resveratrol 150–500 mg | SIRT1 activator + NAD+ fuel split |
| Duration | Minimum 12 weeks | NAD+ metabolites rise by week 2–4 |
Full-day schedule (NAD+ Mito Stack)
| Time | Compound | Dose |
|---|---|---|
| AM (fasted) | NMN | 250–500 mg |
| AM (breakfast) | Ca-AKG | 1–2 g |
| PM (fat meal) | Trans-resveratrol | 150–500 mg |
Week-one compliance checklist
- [ ] Log baseline NAD+ if available; otherwise log energy + resting HR daily
- [ ] Set AM alarm: NMN before coffee
- [ ] Schedule PM resveratrol with dinner (fat improves absorption)
- [ ] Confirm B12/folate adequate if running 6+ months (methyl donor balance)
- [ ] Calendar week 4 NAD+ draw and week 12 review
Add NMN to your stack
Enable NMN + resveratrol — synergyWhen two compounds together produce greater effect than either alone. Full glossary → score and contraindication checks update live.
Open Stack ArchitectMonitoring
| Biomarker | Target | Frequency | Action if off-target |
|---|---|---|---|
| NAD+ index | 80–100 | Baseline, 4 wk, 12 wk | Verify product; audit compliance |
| Fasting glucose | <100 mg/dL | 3 months | Reduce dose if symptomatic hypoglycemia |
| Resting heart rate | ↓2–5 bpm trend | Weekly wearable | If rising → physician review |
| Subjective energy | ≥7/10 morning | Daily | Flat at 12 wk → add PM resveratrol |
← Swipe for more columns →
NAD+ index
55–70
Morning energy
5–6/10
Resting HR
65–72 bpm
Recovery (wearable)
Low
NAD+ index
80+
Morning energy
7–8/10
Resting HR
60–68 bpm
Recovery (wearable)
Moderate+
Safety, red flags, and contraindications
- Generally well tolerated at 250–500 mg in published trials
- Methyl donor drain: Long-term high-dose precursors may increase nicotinamide methylation — ensure B12, folate, betaine if on 6+ month protocols
- Not niacin flush: NMN is not nicotinic acid; flushing suggests wrong product
Do not self-start without clearance
- Active chemotherapy or immunotherapy — NAD+ biology interacts with treatment intent; oncologist clearance required
- Pregnancy or breastfeeding — insufficient human safety data
- Unexplained muscle pain or weakness worsening on NMN — rule out metabolic myopathy
- Fasting glucose falling symptomatically — reduce dose; physician review if persistent
Who should skip NMN
- Anyone under ~40 with no measured NAD+ deficit — you are supplementing a pool that hasn't dropped yet. - People who haven't fixed sleep and exercise — NAD+ precursors are second-line to the biogenesis signals those provide. - Active cancer treatment or pregnancy/breastfeeding — insufficient safety data; oncologist/OB clearance first.
Synergies and antagonists
Pairs well with:
| Partner | Rationale | Guide |
|---|---|---|
| Trans-resveratrol | Activates SIRT1; NMN fuels it | SIRT1 pair |
| Ca-AKG | TCA + epigenetic support | NAD+ Mito Stack |
| GlyNAC | Orthogonal ROS defense while NAD+ restores repair | NRF2 Triad |
Works against / redundant with:
| Antagonist | Conflict | What to do |
|---|---|---|
| High-dose NR | Same NAD+ salvage endpoint — stacking both is redundant spend, not additive | Pick one precursor; don't run high doses of both without oversight |
| High-dose niacin (nicotinic acid) | Overlapping NAD+ route plus flush/lipid effects that confound readouts | Don't combine for NAD+ purposes; if flushing, you have the wrong product |
| Chronic inflammation / high CD38 | CD38 degrades NAD+ faster than precursors restore it | Address the inflammatory driver; CD38-inhibiting flavonoids (apigenin, quercetin) can help |
Personal results template
My NMN results log
| Date | Week | Dose | NAD+ | Energy (1–10) | RHR | Sleep (1–10) | Resveratrol PM? | Notes |
|---|---|---|---|---|---|---|---|---|
| YYYY-MM-DD | 0 | — | — | — | — | — | No | Baseline |
| YYYY-MM-DD | 4 | 250 mg | — | — | — | — | Yes | Early NAD+ check |
| YYYY-MM-DD | 12 | 250–500 mg | — | — | — | — | Yes | Primary endpoint |
| YYYY-MM-DD | 24 | 500 mg | — | — | — | — | Yes | Maintenance |
← Swipe for more columns →
Response criteria (personal, not clinical): - Meaningful: NAD+ ≥80 OR energy ↑2 points + RHR ↓3 bpm - Plateau: NAD+ up but flat energy → confirm PM resveratrol + sleep audit - Adverse: Muscle pain, glucose crashes, insomnia spike → pause and consult
Log your experiment
Document NMN as a milestone — auto-tracked in your Longevity OS dashboard.
Personal journeyReferences
- Yi L et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience (2022). PMID 36482258
- Yoshino M et al. NMN increases muscle insulin sensitivity in prediabetic women. Science (2021). PMID 33888596
- PMID 34238308
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.